SCHEMBL4301248

SCHEMBL4301248

C=CCNc1[c]ccc(N2CCNCC2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ADRB1 P08588 7/20 0.38
CHRNB2 P17787 2/20 0.37
CHRNA4 P43681 2/20 0.37
HTR3E A5X5Y0 4/20 0.37
HTR3B O95264 4/20 0.37
HTR3A P46098 4/20 0.37
HTR3D Q70Z44 4/20 0.37
HTR3C Q8WXA8 4/20 0.37
SIGMAR1 Q99720 4/20 0.37
HRH4 Q9H3N8 3/20 0.37
HTR1A P08908 2/20 0.37
HTR7 P34969 2/20 0.37
HTR2C P28335 2/20 0.37
TP53 P04637 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4295987 0.86 MAPT (0.48) MAPTMEN1KMT2AL3MBTL1CYP1A2
SCHEMBL3513187 0.68 CYP1A2 (0.44) MAPTADRB1HTR3EHTR3BHTR3A
SCHEMBL4600271 0.68 LMNA (0.42) MEN1KMT2AL3MBTL1TP53CYP1A2
SCHEMBL4599615 0.68 LMNA (0.36) MEN1KMT2AL3MBTL1HTR2AALDH1A1
SCHEMBL4598425 0.68 HPGD (0.37) MAPTMEN1KMT2AL3MBTL1CYP1A2
SCHEMBL2388797 0.68 HTR1A (0.47) MAPTADRB1HTR3EHTR3BHTR3A
SCHEMBL17293924 0.68 ADRB1 (0.56) ADRB1HTR3EHTR3BHTR3AHTR3D
SCHEMBL15475075 0.68 ADRB1 (0.47) MAPTADRB1CHRNB2CHRNA4HTR3E
SCHEMBL28316084 0.68 ADRB1 (0.44) MAPTADRB1HTR3EHTR3BHTR3A
SCHEMBL3511179 0.65 HRH4 (0.36) MAPTMEN1KMT2AL3MBTL1HTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP claimed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 MAPT 119/4885MEN1 3177/4885KMT2A 1812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.